NASDAQ:FBIO - Fortress Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.86 -0.12 (-6.06 %) (As of 03/24/2019 07:39 AM ET)Previous Close$1.86Today's Range$1.84 - $1.968552-Week Range$0.49 - $5.22Volume281,571 shsAverage Volume417,456 shsMarket Capitalization$105.42 millionP/E RatioN/ADividend YieldN/ABeta3.23 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.. Receive FBIO News and Ratings via Email Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO Previous Symbol CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone781-652-4500Debt Debt-to-Equity Ratio3.06 Current Ratio2.00 Quick Ratio2.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.88 million Price / Sales3.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book0.78Profitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-66,870,000.00 Net Margins-30.52% Return on Equity-113.66% Return on Assets-40.36%Miscellaneous Employees68 Outstanding Shares56,680,000Market Cap$105.42 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How were Fortress Biotech's earnings last quarter? Fortress Biotech (NASDAQ:FBIO) released its quarterly earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.58) EPS for the quarter, hitting analysts' consensus estimates of ($0.58). Fortress Biotech had a negative net margin of 30.52% and a negative return on equity of 113.66%. View Fortress Biotech's Earnings History. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Fortress Biotech. What price target have analysts set for FBIO? 2 Wall Street analysts have issued twelve-month price targets for Fortress Biotech's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Fortress Biotech's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 491.4% from the stock's current price. View Analyst Price Targets for Fortress Biotech. What is the consensus analysts' recommendation for Fortress Biotech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech. What are Wall Street analysts saying about Fortress Biotech stock? Here are some recent quotes from research analysts about Fortress Biotech stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (2/20/2019) 2. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (2/15/2019) Has Fortress Biotech been receiving favorable news coverage? Media headlines about FBIO stock have trended positive this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fortress Biotech earned a news impact score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest in February. As of February 15th, there was short interest totalling 1,962,630 shares, an increase of 90.7% from the January 31st total of 1,028,922 shares. Based on an average trading volume of 761,448 shares, the days-to-cover ratio is presently 2.6 days. Currently, 5.9% of the company's shares are short sold. View Fortress Biotech's Current Options Chain. Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), Theratechnologies (THERF), Innate Pharma (IPHYF), Achillion Pharmaceuticals (ACHN), OvaScience (OVAS), MannKind (MNKD), Beyondspring (BYSI), XBiotech (XBIT), Aptorum Group (APM), OptiNose (OPTN), Sinovac Biotech (SVA), Progenics Pharmaceuticals (PGNX), Concert Pharmaceuticals (CNCE) and Emisphere Technologies (EMIS). What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Progenics Pharmaceuticals (PGNX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), Inovio Pharmaceuticals (INO), ZIOPHARM Oncology (ZIOP) and Genocea Biosciences (GNCA). Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the folowing people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65) Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.32%), Strs Ohio (0.68%), Geode Capital Management LLC (0.67%), Geode Capital Management LLC (0.67%), Rhumbline Advisers (0.08%) and SG Americas Securities LLC (0.08%). Company insiders that own Fortress Biotech stock include George Avgerinos, Lindsay A Md Rosenwald and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech. Which institutional investors are selling Fortress Biotech stock? FBIO stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd. and BlackRock Inc.. Company insiders that have sold Fortress Biotech company stock in the last year include George Avgerinos and Robyn Hunter. View Insider Buying and Selling for Fortress Biotech. Which institutional investors are buying Fortress Biotech stock? FBIO stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, SG Americas Securities LLC, Geode Capital Management LLC, Geode Capital Management LLC, Shikiar Asset Management Inc., Two Sigma Investments LP and Rhumbline Advisers. View Insider Buying and Selling for Fortress Biotech. How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $1.86. How big of a company is Fortress Biotech? Fortress Biotech has a market capitalization of $105.42 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe. What is Fortress Biotech's official website? The official website for Fortress Biotech is http://www.fortressbiotech.com. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 426MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?